Registry Study of Luminopia Treatment in Patients with Amblyopia Observing Visual Acuity and Treatment Outcomes Over Time

What this Trial Is About

Amblyopia is a common cause of reduced vision in one eye among children and young adults, affecting between 1% to 5% of this population. It often results from untreated differences in vision between the eyes or eye misalignment, and can impact various visual functions including depth perception and reading ability. Researchers are using a patient registry to collect real-world data on Luminopia, an FDA-approved device that offers a new dual action treatment for amblyopia, to understand how it is used by eye care professionals and its effects in everyday practice. This study observes patients who have been treated with Luminopia, a medical device that uses therapeutic software to stimulate vision in the affected eye. The registry collects clinical information over time without altering the standard care these patients receive. By gathering data at multiple points including 3, 6, 12, and 24 months, researchers aim to track changes in visual acuity, stereoacuity, treatment adherence, and treatment duration. Participants provide clinical data through their regular follow-up visits while undergoing Luminopia treatment. Researchers monitor vision improvements and durability of results after stopping treatment using standard clinical assessments. The study also analyzes outcomes based on factors like prior treatments, type and severity of amblyopia, age, and adherence levels. This comprehensive observation will help answer important scientific questions about the long-term real-world use of Luminopia therapy.

Clinical Data Registry of Amblyopia Patients on Luminopia Treatment